Please use this identifier to cite or link to this item:
Title: Imaging biomarkers to track subclinical atherosclerosis in heterozygous familial hypercholesterolemia
Authors: MINAME, Marcio H.SANTOS, Raul D.
Citation: CLINICAL LIPIDOLOGY, v.8, n.2, p.231-242, 2013
Abstract: Heterozygous familial hypercholesterolennia (FH) is characterized by high LDL cholesterol levels and premature coronary heart disease onset. Nonetheless, the course of coronary disease events in heterozygous FH subjects is variable. The presence and severity of subclinical atherosclerosis predicts cardiovascular event onset and may help reclassify the risk of clinical events in the general population. In this review, we discuss the possible use of subclinical coronary, carotid and aortic atherosclerosis testing in heterozygous FH subjects for cardiovascular risk stratification and treatment. Many FH subjects present an increased and precocious burden of subclinical vascular disease in comparison to normolipidemic subjects. These subjects may be at higher risk of cardiovascular events and might deserve more aggressive lipid-lowering treatment. Nevertheless, routine screening of imaging biomarkers for FH subjects in clinical practice remains to be determined in prospective trials.
Appears in Collections:Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor

Files in This Item:
File Description SizeFormat 
  Restricted Access
publishedVersion (English)3.76 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.